Vanguard holds 5.21% stake in Cytokinetics (NASDAQ: CYTK) via 6.42M shares

Rhea-AI Filing Summary

Cytokinetics Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 6,422,042 shares of Cytokinetics common stock, constituting 5.21% of the class as of 03/31/2026. The filing lists sole voting power of 933,408 shares and sole dispositive power over all reported shares.

Insights

Institutional Ownership Analyst

Vanguard holds a >5% passive stake in Cytokinetics.

Vanguard Capital Management reported beneficial ownership of 5.21% as of 03/31/2026, with 6,422,042 shares and sole dispositive power over those shares. The filing is a routine Schedule 13G disclosure for an institutional investor.

Implications are neutral: the stake signals institutional interest but the filing does not indicate an activist intent or a change in control. Subsequent filings could show changes in voting arrangements or percent ownership.

Key Figures

Beneficial ownership: 6,422,042 shares Percent of class: 5.21% Sole voting power: 933,408 shares +1 more

4 metrics

Beneficial ownership 6,422,042 shares reported as of 03/31/2026

Percent of class 5.21% percent of common stock as reported

Sole voting power 933,408 shares shares with sole power to vote

Sole dispositive power 6,422,042 shares shares with sole power to dispose

Key Terms

Schedule 13G, Sole dispositive power, Beneficial ownership, Investment Company Act of 1940

4 terms

Schedule 13G regulatory

"Vanguard Capital Management files a Schedule 13G reporting beneficial ownership"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Sole dispositive power financial

"Sole power to dispose or to direct the disposition of: 6,422,042"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Beneficial ownership regulatory

"Amount beneficially owned: 6422042 (b) Percent of class: 5.21 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Investment Company Act of 1940 regulatory

"A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 is not required"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cytokinetics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23282W605

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 23282W605

1

Names of Reporting Persons

Vanguard Capital Management

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 933,408.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 6,422,042.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

6,422,042.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.21 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cytokinetics Inc
(b)	Address of issuer's principal executive offices: 350 Oyster Point Blvd, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: Vanguard Capital Management
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd,, Malvern, PA, 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 23282W605
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 6422042
(b)	Percent of class: 5.21 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 933408
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 6422042
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vanguard Capital Management

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	04/29/2026

FAQ

What stake does Vanguard hold in Cytokinetics (CYTK)?

Vanguard Capital Management reports beneficial ownership of 6,422,042 shares, representing 5.21% of Cytokinetics common stock as of 03/31/2026. The filing shows sole dispositive power over these shares and sole voting power for 933,408 shares.

What does sole dispositive power mean in the CYTK filing?

Sole dispositive power means Vanguard has the authority to direct the sale of the reported 6,422,042 shares. The Schedule 13G indicates Vanguard exercises dispositive power for those shares, as disclosed in the filing dated 03/31/2026.

Is Vanguard an activist investor in Cytokinetics based on this filing?

This Schedule 13G reports passive beneficial ownership of 5.21% and does not state activist intent. The filing lists voting and dispositive powers but does not indicate plans to influence management or seek control in Cytokinetics.

Who signed the Schedule 13G for Vanguard in the CYTK filing?

The filing is signed by Ashley Grim, Head of Global Fund Administration, with a signature date of 04/29/2026. The Schedule 13G lists Vanguard Capital Management as the reporting person and provides its Malvern, PA address.

Does the CYTK filing include shares held by Vanguard funds?

Yes. The disclosure states it includes securities held by Vanguard funds and managed accounts over which Vanguard Capital Management or certain affiliates exercise dispositive power, per the explanatory paragraph in the filing.